Molecular Residual Disease Analysis May Predict Disease Recurrence After Lung Cancer Resection

Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion
lung cancer
Adobe Stock
Medically Reviewed By:
Farrokh Sohrabi, M.D.
Published on
Updated on
Loading content, please wait...

Related Stories

No stories found.
logo
www.healthday.com